表紙
市場調查報告書

通用注射劑2020-產品,市場和參與者

Generic Injectables 2020 - Products, Markets and Players

出版商 Greystone Research Associates 商品編碼 947987
出版日期 內容資訊 英文 160 Pages
商品交期: 最快1-2個工作天內
價格
通用注射劑2020-產品,市場和參與者 Generic Injectables 2020 - Products, Markets and Players
出版日期: 2020年07月07日內容資訊: 英文 160 Pages
簡介

本報告分析了全球通用注射劑市場,並分析了市場的基本結構和背景(法規,經濟學等),主要驅動因素/抑制因素,總體市場規模前景以及藥品。我們將按類別,治療類別,ANDA(縮寫為新藥申請)註冊策略的趨勢,專利競爭和訴訟狀態以及市場影響收集詳細信息。

內容

執行摘要

市場機會

  • 注射劑市場結構
  • 注塑市場增長趨勢

仿製藥:成長要因

  • 專利和排他性
  • 訴訟和先申請(FTF)下的ANDA策略
  • 買賣ANDA(新藥批准申請的縮寫)

通用注射產品注意事項

  • 提供的容器
  • 凍乾/重組
  • 藥物因素

仿製藥市場分析

藥物分類分析

  • 腎上腺素能激動劑
  • 助劑
  • 抗生素
  • 美學
  • 抗心律失常藥
  • 抗凝劑
  • 抗驚厥藥
  • 止吐藥
  • 抗炎藥
  • 降壓藥
  • 抗腫瘤藥
  • 抗病毒藥
  • 骨吸收抑製劑
  • 利尿劑
  • 葉酸代謝產物
  • 生長激素
  • 抑製劑
  • 肌肉鬆弛劑
  • 麻醉止痛藥
  • 神經遞質
  • 阿片類拮抗劑
  • 鎮靜劑
  • 血管擴張藥

治療類別分析

  • 循環器
  • 神經
  • 疼痛管理
  • 其他專業

市場因素

  • 法規問題
  • 訴訟問題
  • ANDA歸檔策略的發展
  • CMO(合同藥品製造組織)的作用
  • 衛生經濟學
目錄

Tracking a Moving Target

The generic injectable drug segment is a rapidly evolving and highly unpredictable environment that lacks a true data compass to assist decision makers in mapping strategies for success in this segment. There are 248 distinct APIs for which there is at least one approved generic injectable ANDA. These 248 APIs account for 1,223 approved ANDAs. Including all approved doses, the current universe of generic injectables consists of 1,746 unique injectable products. These products are marketed and supplied by slightly less than one hundred companies.

Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

What You Will Learn:

  • Provides detailed analysis of generic drugs supplied as injectables and assesses key market segments, market dynamics and potential product opportunities
  • Presents the competitive picture for generic injectables in two dozen drug classes
  • Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
  • Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
  • Assesses the market presence and product position of the top twenty-four generic injectables suppliers
  • Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

Executive Summary

The Market Opportunity

  • The Economics of Injectable Drugs
  • Growth in Injectables

Generic Injectables - Growth Factors

  • Patents and Exclusivity
  • Litigation and First-to-File ANDA Strategies
  • Buying and Selling ANDAs

Generic Injectables - Product Considerations

  • As-supplied Container
  • Lyophilization/Reconstitution
  • Formulation Factors

Generic Injectables Market Analysis

Drug Class Analysis

  • Adrenergic Agents
  • Anabolic Agents
  • Antibiotics
  • Anesthetics
  • Antiarrhythmics
  • Anticoagulants
  • Anticonvulsants
  • Antiemetics
  • Anti-inflammatory
  • Antihypertensives
  • Antineoplastics
  • Antivirals
  • Bone Resorption Inhibitors
  • Diuretics
  • Folic Acid Metabolites
  • Growth Hormone
  • Inhibitors
  • Muscle Relaxants
  • Narcotic Analgesics
  • Neurotransmitter
  • Opioid Antagonist
  • Sedatives
  • Vasodilators

Therapeutic Class Analysis

  • Cardiology
  • Hematology
  • Neurology
  • Pain Management
  • Other Key Classes

Market Factors

  • Regulatory Issues
  • Litigation Issues
  • Evolving ANDA Filing Strategies
  • The Role of CMOs
  • Healthcare Economics